Program
elismetrep
Also written as “MT-8554”, “Elismetrep” and “MT-8554 low dose”.
Its studies are mostly in Migraine Disorders · Hot Flashes, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tanabe Pharma | 100 open or running | phase 2since May 29, 2017 | Apr 16, 2015 | none ahead |
| TriGemX Bio | 43 open or running | phase 3since Jun 9, 2026 | Feb 21, 2025 | Feb 2027phase 3 · NCT07645924 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 16, 2015First study: phase 1 study in HealthyNew to Tanabe PharmaTanabe Pharma · NCT02429102 · 135 enrolled · United Kingdom
- Aug 16, 2015Phase 1 study in HealthyTanabe Pharma · NCT02536209 · 20 enrolled · United Kingdom
- Feb 3, 2016Phase 1 study in HealthyTanabe Pharma · NCT02675309 · 28 enrolled · United Kingdom
- Jun 14, 2016Phase 1 study in Vasomotor SymptomsTanabe Pharma · NCT02803268 · 24 enrolled · Germany
- May 29, 2017Phase 2 study in Painful Diabetic Peripheral NeuropathyTanabe Pharma · NCT03172598 · 61 enrolled · Germany, Hungary, Poland
- Sep 20, 2017Phase 2 study in Menopause Hot FlashesTanabe Pharma · NCT03291067 · 375 enrolled · United States
- Nov 29, 2017Phase 1 study in Healthy VolunteerTanabe Pharma · NCT03381404 · 6 enrolled · United Kingdom
- Feb 28, 2018Phase 1 study in Healthy VolunteerTanabe Pharma · NCT03471130 · 48 enrolled · United Kingdom
- Mar 29, 2018Phase 2 study in Vasomotor Symptoms (VMS)Tanabe Pharma · NCT03541200 · 190 enrolled · United States
- Oct 18, 2021Phase 2 study in Painful Diabetic Peripheral NeuropathyTanabe Pharma · NCT05123196 · 156 enrolled · Japan
- Feb 21, 2025TriGemX Bio's first study: phase 2 study in Migraine DisordersNew to TriGemX BioTriGemX Bio · NCT06848075 · 431 enrolled · United States
- Jun 9, 20262 phase 3 studiesPhase 3 reachedTriGemX Bio · NCT07645924, NCT07674654
- Sep 7, 2026Phase 3 study in Migraine DisordersTriGemX Bio · NCT07816367 · 1,500 planned · United States
Ahead
- Feb 2027Primary completion: phase 3 study in Migraine DisordersTriGemX Bio · NCT07645924
- Oct 2027Primary completion: phase 3 study in Migraine DisordersTriGemX Bio · NCT07816367
- Jun 2028Primary completion: phase 3 study in Acute MigraineTriGemX Bio · NCT07674654
TargetBeta
“Transient receptor potential cation channel subfamily M member 8 inhibitor”ChEMBL 37, by rule
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07816367Migraine Disorders · United States | 3 | Recruiting | TriGemX Bio | Oct 2027 | 1,500 |
| NCT07674654Acute Migraine · United States | 3 | Recruiting | TriGemX Bio | Jun 2028 | 1,000 |
| NCT07645924Migraine Disorders · United States | 3 | Recruiting | TriGemX Bio | Feb 2027 | 1,800 |
| NCT06848075Migraine Disorders · United States | 2 | Completed | TriGemX Bio | Aug 4, 2025 | 431 |
| NCT05123196Painful Diabetic Peripheral Neuropathy · Japan | 2 | Completed | Tanabe Pharma | Nov 1, 2022 | 156 |
| NCT03541200Vasomotor Symptoms (VMS) · United States | 2 | Completed | Tanabe Pharma | Nov 15, 2019 | 190 |
| NCT03471130Healthy Volunteer · United Kingdom | 1 | Completed | Tanabe Pharma | Oct 19, 2018 | 48 |
| NCT03381404Healthy Volunteer · United Kingdom | 1 | Completed | Tanabe Pharma | Jan 29, 2018 | 6 |
| NCT03291067Menopause Hot Flashes · United States | 2 | Completed | Tanabe Pharma | Oct 19, 2018 | 375 |
| NCT03172598Painful Diabetic Peripheral Neuropathy · Germany, Hungary, Poland | 2 | Completed | Tanabe Pharma | Aug 8, 2018 | 61 |
| NCT02803268Vasomotor Symptoms · Germany | 1 | Completed | Tanabe Pharma | Jan 2017 | 24 |
| NCT02675309Healthy · United Kingdom | 1 | Completed | Tanabe Pharma | Mar 2016 | 28 |
| NCT02536209Healthy · United Kingdom | 1 | Completed | Tanabe Pharma | Nov 2015 | 20 |
| NCT02429102Healthy · United Kingdom | 1 | Completed | Tanabe Pharma | Nov 2015 | 135 |
How it is read
Names in the registry
- “MT-8554”, 4 entries
- “Elismetrep”, 3 entries
- “MT-8554 low dose”, 3 entries
- “MT-8554 high dose”, 3 entries
- “MT-8554 middle dose”, 2 entries
Conditions, from the studies’ own filings
- Migraine Disorders, 4 studies
- Hot Flashes, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.